in-Pharmatechnologist.com spoke with company head of Biopharm Process Solutions Paul Chapman at Interphex 2011, who said the traditional focus on boosting bioreactor titres should be replaced by a holistic approach to optimisation.
“Our research suggests that [biomanufacturing efficiency] is not just about optimising the bioreactor and then trying to manage the titres downstream...we have to make sure we’ve looked at the entire process.”
He went on to explain that, increasingly, EMD Millipore’s customers are recognising the need for integrated manufacturing and that this is driving the development of the next generation of production technologies like those the firm had on show at Interphex this year.
Chapman also spoke about integration on the corporate level, explaining that Merck KGaA’s $7bn acquisition of Millipore last summer has provided a number of significant growth opportunities for EMD Millipore.
“It’s been great,” he commented, adding that “We talk about integration of our thinking around the whole [biomanufacturing] process.
“Having Merck KGaA with all of their expertise, particularly Merck Serono and EMD Serono in the US…really helps us to look at the whole integrated manufacturing process.”